The Motley Fool

Is Ekf Diagnostics Holding plc a buy as shares jump 10%+?

Point-of-care specialist EKF Diagnostics (LSE: EKF) has released an upbeat trading update today with plenty of good news on revenues, earnings and investment plans. But does that mean now is the right time to buy it?

EKF’s third quarter of the year was a successful one. It was materially higher than budget and at a run-rate above and beyond market forecasts. EKF now expects to record revenues and adjusted EBITDA (earnings before interest, tax, depreciation and amortisation) for 2016 that will exceed even the high end of current market forecasts.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Additionally, EKF has also announced that its cash generation during the third quarter has been strong and its net debt position has therefore been boosted considerably. Although EKF is expected to continue to invest for long-term growth through to the end of the year, it now expects to be cash positive within the next year. Crucially, this won’t be to the detriment of capex to increase consumables capacity in Germany and to replace equipment in the US.

The market has reacted positively to EKF’s update. Its shares are up by 15% and this takes them to a rise of 52% in the last six months. Looking ahead, there could be more capital gains to come, since EKF offers stunning earnings growth forecasts at a very reasonable price.

For example, EKF is expected to turn a profit in the current year after five years of straight losses. Next year, its bottom line is forecast to rise by 134% and this puts it on a price-to-earnings growth (PEG) ratio of just 0.3. This indicates that it offers significant upward rerating potential and it would therefore be unsurprising for it to continue to beat the wider index.

Upbeat outlook

Of course, there are other options within the healthcare space. A notable example is Smith & Nephew (LSE: SN). It offers a lower risk profile than EKF since it has an excellent track record of profitability. It also has a much stronger balance sheet, superior cash flow and greater diversity in terms of its product offering and geographic exposure.

Furthermore, Smith & Nephew offers an upbeat outlook. Its bottom line is expected to grow by 13% in the next financial year and this puts it on a PEG ratio of just 1.4. This shows that while Smith & Nephew is a large cap that may not be able to compete with smaller peers in terms of growth, it nevertheless offers substantial capital gain potential.

In fact, Smith & Nephew’s risk/reward ratio is more appealing than that of EKF. Certainly, EKF is worth buying due to its rapid improvement, growth prospects and low valuation. However, Smith & Nephew’s lower risk and still relatively high reward prospects make it the better overall investment for the long term.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Peter Stephens has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.